ASP 4070

Drug Profile

ASP 4070

Alternative Names: ASP-4070; CryJ2 -DNA-LAMP; CryJ2 DNA LAMP plasmid vaccine; CryJ2-DNA-lysosomal associated membrane protein plasmid; Japanese red cedar LAMP vaccine; Japanese red cedar pollen allergy immunotherapy - Immunomic; JRC LAMP vaccine; JRC LAMP vax vaccine; JRC-LAMP-vax; JRC2-LAMP-vax; Sugi allergy vaccine

Latest Information Update: 03 May 2017

Price : $50

At a glance

  • Originator Immunomic Therapeutics
  • Developer Astellas Pharma; Immunomic Therapeutics
  • Class DNA vaccines; Japanese cedar pollen allergy immunotherapies; Vaccines
  • Mechanism of Action Th1 cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Tree pollen hypersensitivity
  • Phase I Allergic rhinitis
  • No development reported Allergic rhinoconjunctivitis

Most Recent Events

  • 18 Apr 2017 Astellas Pharma plans a phase II trial for Tree-pollen hypersensitivity in Japan (NCT03101267)
  • 13 Apr 2017 Phase-II clinical trials in Tree pollen hypersensitivity in Japan (Intradermal) (NCT03101267)
  • 22 Nov 2016 Immunomic Therapeutics has patent protection for LAMP-Vax™ technology in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top